The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

Phillips 66, Edwards Lifesciences, Newmont & Gilead rise premarket on strong Q2 earnings, upgrades, and key advancements.

Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday.

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...